Champignon Brands forms North American planning committee to accelerate US expansion
The ketamine clinic operator is in the midst of discussions with revenue-generating clinics in six states as part of its goal to open five US clinics in 2020
Sector
Health
988 stories · page 45 of 50
Champignon Brands closes deal to acquire ketamine clinic operator AltMed Capital
AltMed recently gained full ownership of the Canadian Rapid Treatment Centre of Excellence
Champignon Brands makes ketamine treatment available at major Canadian pharmacy location
The group will also leverage the pharmacy’s infrastructure to distribute ketamine topical prescriptions to a network of medical, pain and addiction clinics in Canada
Champignon Brands chosen as headline partner for major psychedelics conference in June
The Vancouver-based company will be a main partner for PSYCH: The Psychedelics Symposium, which is scheduled to run virtually between June 22 to 23
Champignon Brands shares begin to trade on the OTCQB Venture Market
The move to the OTCQB opens up a broader base of investors in the US for the Vancouver-based company, which specializes in the formulation of a suite of medicinal mushroom health products
Champignon secures stable psilocybin supply for traumatic brain injury, PTSD studies at the University of Miami
The group has obtained a long-term supply of psilocybin under a Drug Enforcement Administration schedule I license for psilocybin-based studies
Champignon Brands receives DTC eligibility for easier US trading
The Vancouver-based company is 'actively engaged' in pursuing new avenues of distribution both in North America and internationally
Champignon Brands appoints Jim Bailey, former president of Red Bull Canada, to its special advisory committee
He will champion the company’s Novoformulations-branded delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries
Skin Elements shares surge after securing $10.5 million for global rollout of hand sanitisers
Skin Elements and Holista Colltech recently signed a binding agreement to launch a natural alcohol-free hand sanitiser.
Champignon Brands inks blockbuster deal to roll out network of psychedelic medicine clinics in North America
The firm's acquisition of AltMed Capital gives it a fully operational ketamine clinic and cutting-edge intellectual property
Parallax Health Sciences seeking to expand remote patient-monitoring platform
The California company's proprietary platform Parallax Care tracks patients’ vital signs for adherence to their medical and drug regimens
OTC Market’s virtual conference for life sciences companies will be broadcast live on March 26
Investors can pre-register for the Life Sciences Investor Forum — there are no costs to log-in, attend the live presentations or ask questions
Parallax Health accepting US orders for its coronavirus Point-of-Care diagnostics kits
The company is also providing immediate access to Personal Protection Equipment such as medical masks and protective sterile gowns
Humanigen planning Phase III clinical trial for lenzilumab to treat coronavirus patients; shares soar
Those with severe cases of the virus experience pneumonia that can progress to acute respiratory distress syndrome (ARDS)
Q BioMed marks another milestone with first patient dosed with Strontium89
It expects this to be the first of thousands of patients dosed with the FDA approved drug in the coming years
OptiBiotix Health strikes new deal in Bulgaria
Velinoff Pharma will promote and distribute the CholBiome and CholBiomeX3 brands, which contain the company’s LPLDL probiotic bacteria strain
Nemaura Medical strikes new verbal pacts to market flagship diabetes monitor sugarBEAT
Its goal is to forge an array of regional and global partnerships to bring sugarBEAT to market
Humanigen eyes evaluating lenzilumab in treating lung damage caused by coronavirus
It cited a recent study that looked at samples from patients with severe pneumonia resulting from the virus
ReNeuron encouraged by 12-month data from cell therapy for degenerative eye disease
The update was provided alongside news the group had applied to the US regulator to add a further nine people to its phase I/IIa clinical study
Matinas BioPharma to start Part 2 study of MAT2203 to treat HIV patients with cryptococcal meningitis
The announcement comes after data from Part 1 demonstrated that MAT2203 was safe and well-tolerated